Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Приверженность лечению – одна из ключевых детерминант эффективности антигипертензивной терапии: возможности комбинации ирбесартана с гидрохлоротиазидом
Приверженность лечению – одна из ключевых детерминант эффективности антигипертензивной терапии: возможности комбинации ирбесартана с гидрохлоротиазидом
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обсуждается значение приверженности антигипертензивной терапии как фактора, способствующего достижению целевого артериального давления. Представлены причины ухудшения приверженности антигипертензивной терапии. Продемонстрировано, что фиксированная комбинация ирбесартана и гидрохлоротиазида характеризуется хорошими эффективностью и переносимостью.
Ключевые слова: приверженность, антигипертензивная терапия, целевое артериальное давление, ирбесартан, гидрохлоротиазид.
Key words: adherence, antihypertensive therapy, goal blood pressure, irbesartan, hydro-chlorothiazide
Ключевые слова: приверженность, антигипертензивная терапия, целевое артериальное давление, ирбесартан, гидрохлоротиазид.
________________________________________________
Key words: adherence, antihypertensive therapy, goal blood pressure, irbesartan, hydro-chlorothiazide
Полный текст
Список литературы
1. Frohlich ED. The necessity for recognition and treatment of patients with «mild» hypertension. J Am Coll Cardiol 1999; 34: 1369–77.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.
3. Wolf-Maier K, Cooper RS, Kramer H. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7.
4. Macedo ME, Lima MJ, Silva AO et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens 2005; 23: 1661–6.
5. Brindel P, Hanon O, Dartigues JF et al. Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City study. J Hypertens 2006; 24: 51–8.
6. Borghi C, Dormi A, D'Addato S et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22: 1707–16.
7. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертензия: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50.
8. Российское медицинское общество по артериальной гипертонии – Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). Кардиоваск. тер. и проф. 2008; 7 (6, Прил. 2).
9. Чазова И.Е., Фомин В.В. Резистентная артериальная гипертензия. Тер. арх. 2008; 6: 72–9.
10. Garg JP, Elliott WJ, Folker A et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18 (5; 1): 619–26.
11. Degli Esposti L, Degli Esposti E, Valpiani G et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24: 1347–57.
12. Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–55.
13. Saguner AM, Dur S, Perrig M et al. Risk factors promoting hypertensive crises: evidence from a longitudinal study. Am J Hypertens 2010; 23 (7): 775-80.
14. Колос И.П., Чазова И.Е., Терещенко С.Н., Наконечников С.Н. Риск сердечно-сосудистых осложнений у больных с частыми гипертоническими кризами. Тер. арх. 2009; 81 (9): 9–12.
15. Dragomir A, Cote R, Roy L et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48 (5): 418–25.
16. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12 (3): 239–45.
17. Fodor GJ, Kotrec M, Bacskai K et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J Hypertens 2005; 23: 1261–6.
18. Roth A, Kalter-Leibovici O, Kerbis Y et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol 2003; 26: 25–30.
19. Aranda P, Ruilope LM, Calvo C et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004; 17: 139-45.
20. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother 2002; 36: 986-91.
21. Salas M, In't Veld BA, van der Linden PD et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001; 70: 561–6.
22. Alam MG, Barri YM. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am J Hypertens 2003; 16: 140-3.
23. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147-52.
24. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722–32.
25. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.
26. Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24: 302–16.
27. Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance Praxis Survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. J Hum Hypertens 2002; 16: 779–87.
28. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother 2002; 36: 986-91.
29. Visser LE, Stricker BH, van der Velden J et al. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol 1995; 48: 851–7.
30. Chapman RH, Petrilla AA, Benner JS et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging 2008; 25 (10): 885–92.
31. Sung SK, Lee SG, Lee KS et al. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther 2009; 31 (6): 1309–20.
32. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертензии. Сердце 2005; 4 (3): 120–6.
33. Raskin P, Guthrie R, Flack J et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999; 13 (10): 683–7.
34. Rosenstock J, Rossi L, Lin CS et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998; 23 (6): 433–40.
35. Neutel JM, Franklin SS, Oparil S et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006; 8 (12): 850–7.
36. Neutel JM, Franklin SS, Bhaumik A et al. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. Clin Exp Hypertens 2009; 31 (7): 572–84.
37. Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clin Ther 2008; 30 (12): 2354–65.
38. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7 (2): 140–5.
39. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сons Med 2006; 8 (11): 25–30.
40. Sowers JR, Neutel JM, Saunders E et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006; 8 (7): 470–80.
41. Neutel JM, Saunders E, Bakris GL et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005; 7 (10): 578–6.
42. Chrysant SG, Neutel JM, Ferdinand KC. INCLUSIVE investigators. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J Natl Med Assoc 2009; 101 (4): 300–7.
43. Schmieder RE, Schwertfeger M, Bramlage P. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag 2009; 5: 991–1000.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.
3. Wolf-Maier K, Cooper RS, Kramer H. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7.
4. Macedo ME, Lima MJ, Silva AO et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens 2005; 23: 1661–6.
5. Brindel P, Hanon O, Dartigues JF et al. Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City study. J Hypertens 2006; 24: 51–8.
6. Borghi C, Dormi A, D'Addato S et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22: 1707–16.
7. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертензия: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50.
8. Российское медицинское общество по артериальной гипертонии – Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). Кардиоваск. тер. и проф. 2008; 7 (6, Прил. 2).
9. Чазова И.Е., Фомин В.В. Резистентная артериальная гипертензия. Тер. арх. 2008; 6: 72–9.
10. Garg JP, Elliott WJ, Folker A et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18 (5; 1): 619–26.
11. Degli Esposti L, Degli Esposti E, Valpiani G et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24: 1347–57.
12. Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–55.
13. Saguner AM, Dur S, Perrig M et al. Risk factors promoting hypertensive crises: evidence from a longitudinal study. Am J Hypertens 2010; 23 (7): 775-80.
14. Колос И.П., Чазова И.Е., Терещенко С.Н., Наконечников С.Н. Риск сердечно-сосудистых осложнений у больных с частыми гипертоническими кризами. Тер. арх. 2009; 81 (9): 9–12.
15. Dragomir A, Cote R, Roy L et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48 (5): 418–25.
16. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12 (3): 239–45.
17. Fodor GJ, Kotrec M, Bacskai K et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J Hypertens 2005; 23: 1261–6.
18. Roth A, Kalter-Leibovici O, Kerbis Y et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol 2003; 26: 25–30.
19. Aranda P, Ruilope LM, Calvo C et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004; 17: 139-45.
20. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother 2002; 36: 986-91.
21. Salas M, In't Veld BA, van der Linden PD et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001; 70: 561–6.
22. Alam MG, Barri YM. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am J Hypertens 2003; 16: 140-3.
23. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147-52.
24. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722–32.
25. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.
26. Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24: 302–16.
27. Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance Praxis Survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. J Hum Hypertens 2002; 16: 779–87.
28. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother 2002; 36: 986-91.
29. Visser LE, Stricker BH, van der Velden J et al. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol 1995; 48: 851–7.
30. Chapman RH, Petrilla AA, Benner JS et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging 2008; 25 (10): 885–92.
31. Sung SK, Lee SG, Lee KS et al. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther 2009; 31 (6): 1309–20.
32. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертензии. Сердце 2005; 4 (3): 120–6.
33. Raskin P, Guthrie R, Flack J et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999; 13 (10): 683–7.
34. Rosenstock J, Rossi L, Lin CS et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998; 23 (6): 433–40.
35. Neutel JM, Franklin SS, Oparil S et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006; 8 (12): 850–7.
36. Neutel JM, Franklin SS, Bhaumik A et al. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. Clin Exp Hypertens 2009; 31 (7): 572–84.
37. Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clin Ther 2008; 30 (12): 2354–65.
38. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7 (2): 140–5.
39. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сons Med 2006; 8 (11): 25–30.
40. Sowers JR, Neutel JM, Saunders E et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006; 8 (7): 470–80.
41. Neutel JM, Saunders E, Bakris GL et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005; 7 (10): 578–6.
42. Chrysant SG, Neutel JM, Ferdinand KC. INCLUSIVE investigators. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J Natl Med Assoc 2009; 101 (4): 300–7.
43. Schmieder RE, Schwertfeger M, Bramlage P. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag 2009; 5: 991–1000.
Авторы
В.В.Фомин
Научно-исследовательский центр, кафедра терапии и профболезней Первого Московского государственного медицинского университета им. И.М.Сеченова
Department of Therapy and Occupational Diseases, I.M.Sechenov First Moscow State Medical University
Научно-исследовательский центр, кафедра терапии и профболезней Первого Московского государственного медицинского университета им. И.М.Сеченова
________________________________________________
Department of Therapy and Occupational Diseases, I.M.Sechenov First Moscow State Medical University
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.